派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000403 派林生物

已收盘 07-02 15:00:00

{"stockData":{"symbol":"000403","market":"SZ","secType":"STK","nameCN":"派林生物","latestPrice":27.8,"timestamp":1719903822000,"preClose":27.5,"halted":0,"volume":6002259,"delay":0,"floatShares":688000000,"shares":733000000,"eps":0.9245,"marketStatus":"已收盘","marketStatusCode":5,"change":0.3,"latestTime":"07-02 15:00:00","open":27.49,"high":27.97,"low":27.38,"amount":167000000,"amplitude":0.0215,"askPrice":27.8,"askSize":55,"bidPrice":27.74,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.9245,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1719970200000},"adr":0,"adjPreClose":27.5,"symbolType":"stock","openAndCloseTimeList":[[1719883800000,1719891000000],[1719896400000,1719903600000]],"highLimit":30.25,"lowLimit":24.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":733043291,"pbRate":2.67,"roa":"--","roe":"1.63%","epsLYR":0.8384,"committee":-0.271605,"marketValue":20379000000,"floatMarketCap":19125000000,"peRate":30.070309,"changeRate":0.0109,"turnoverRate":0.0087,"status":0},"requestUrl":"/m/hq/s/000403","defaultTab":"news","newsList":[{"id":"2446435764","title":"万联证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446435764","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446435764?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:40","pubTimestamp":1719394843,"startTime":"0","endTime":"0","summary":"万联证券股份有限公司黄婧婧近期对派林生物进行研究并发布了研究报告《首次覆盖：陕煤入主赋能，公司有望通过内生外延稳健增长》，本报告对派林生物给出买入评级，当前股价为26.97元。截至2023年年报，广东双林和派斯菲科分别有血制品品种8个和9个，公司合计有11个品种。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为30.4。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600036104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000403"],"gpt_icon":0},{"id":"2445738840","title":"派林生物(000403.SZ)2023年度每10股派1.999297元 股权登记日为6月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2445738840","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445738840?lang=zh_cn&edition=full","pubTime":"2024-06-21 16:15","pubTimestamp":1718957752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)发布公告，公司将实施2023年度利润分配，向全体股东每10股派1.999297元，股权登记日为6月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2442389554","title":"血液制品概念盘中拉升，派林生物涨3.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442389554","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442389554?lang=zh_cn&edition=full","pubTime":"2024-06-11 11:07","pubTimestamp":1718075236,"startTime":"0","endTime":"0","summary":"06月11日，血液制品概念盘中拉升，截至11点07分，血液制品概念整体指数上涨1.02%，报756.830点。从个股上来看，该概念的成分股中，派林生物涨3.84%，同方股份、卫光生物、博雅生物涨幅居前。从资金上来看，截止发稿，血液制品概念概念主力净流入为-4992.90万，其中同方股份受到资金热捧，主力净流入693.96万；拉长时间线来看，该板块近20日主力资金净流入-9.67亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240611110716aef440e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240611110716aef440e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0214","BK0188","BK0067","BK0043","BK0101","BK0196","BK0124","000403","BK0028","BK0239","600100","BK0041","BK0045","BK0026","BK0030","BK0038","BK0122","BK0071"],"gpt_icon":0},{"id":"2442680422","title":"派林生物（000403）6月7日主力资金净卖出290.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442680422","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442680422?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:21","pubTimestamp":1718068894,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月7日收盘，派林生物报收于27.83元，下跌2.21%，换手率1.13%，成交量7.79万手，成交额2.17亿元。6月7日的资金流向数据方面，主力资金净流出290.82万元，占总成交额1.34%，游资资金净流入2510.12万元，占总成交额11.56%，散户资金净流出2219.3万元，占总成交额10.22%。融券方面，融券卖出2.55万股，融券偿还10.37万股，融券余量44.98万股，融券余额1251.92万元。派林生物主营业务：血液制品的研究、开发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2439981158","title":"派林生物（000403）5月30日主力资金净卖出815.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439981158","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439981158?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:15","pubTimestamp":1717118110,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月30日收盘，派林生物报收于27.24元，上涨2.29%，换手率1.01%，成交量6.95万手，成交额1.9亿元。5月30日的资金流向数据方面，主力资金净流出815.71万元，占总成交额4.29%，游资资金净流入1437.77万元，占总成交额7.57%，散户资金净流出622.06万元，占总成交额3.27%。融券方面，融券卖出2.99万股，融券偿还7200.0股，融券余量55.46万股，融券余额1510.86万元。派林生物主营业务：血液制品的研究、开发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100013301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2439542413","title":"派林生物：公司截止2024年5月20日股东人数为17853户","url":"https://stock-news.laohu8.com/highlight/detail?id=2439542413","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439542413?lang=zh_cn&edition=full","pubTime":"2024-05-29 19:02","pubTimestamp":1716980578,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物05月29日在投资者关系平台上答复投资者关心的问题。公司截止2024年5月20日股东人数为17853户。投资者：请问董秘，昨天回复的股东人数23年5月10日是不是有误？投资者：董秘，请问公司2023年分红什么时间实施，公司未来是否会提高分红比例？2023年分红将在2023年年度股东大会审议通过后2个月内尽快实施，请关注公司发布公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052900036385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2439714562","title":"海通国际：给予派林生物增持评级，目标价位31.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439714562","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439714562?lang=zh_cn&edition=full","pubTime":"2024-05-29 11:55","pubTimestamp":1716954917,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng,Wenxin Yu,Qin Zheng,Ping Peng近期对派林生物进行研究并发布了研究报告《公司年报点评：采浆同比大幅增长，盈利能力稳步提升》，本报告对派林生物给出增持评级，认为其目标价位为31.80元，当前股价为26.31元，预期上涨幅度为20.87%。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为29.7。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052900023250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"gpt_icon":0},{"id":"2437323732","title":"派林生物：公司截止2024年5月20日股东人数17853户","url":"https://stock-news.laohu8.com/highlight/detail?id=2437323732","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437323732?lang=zh_cn&edition=full","pubTime":"2024-05-23 19:02","pubTimestamp":1716462142,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)05月23日在投资者关系平台上答复投资者关心的问题。投资者：请问贵公司截止到五月二十日股东人数是多少？谢谢派林生物董秘：尊敬的投资者，您好！公司截止2024年5月20日股东人数17853户。谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300034092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2437282263","title":"派林生物最新公告：子公司获得静注人免疫球蛋白（10%）临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2437282263","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437282263?lang=zh_cn&edition=full","pubTime":"2024-05-22 18:49","pubTimestamp":1716374978,"startTime":"0","endTime":"0","summary":"派林生物公告，近日，公司之全资子公司广东双林生物制药有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，经审查，2023年8月1日受理的静注人免疫球蛋白（10%）符合药品注册的有关要求，同意开展适应症为原发免疫性血小板减少症的临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200033679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1141","BK1576","BK1583","000403","BK0071","03347"],"gpt_icon":0},{"id":"2437250715","title":"派林生物(000403.SZ)：静注人免疫球蛋白(10%)获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2437250715","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437250715?lang=zh_cn&edition=full","pubTime":"2024-05-22 18:30","pubTimestamp":1716373832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，相关药物名称为：静注人免疫球蛋白(10%)，同意开展适应症为原发免疫性血小板减少症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","03347","BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2434569458","title":"5月10日派林生物发布公告，其股东减持599.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434569458","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434569458?lang=zh_cn&edition=full","pubTime":"2024-05-10 21:01","pubTimestamp":1715346071,"startTime":"0","endTime":"0","summary":"证券之星消息，5月10日派林生物发布公告《派林生物:关于持股5%以上股东股份减持计划实施完成的公告》，其股东杨峰于2024年3月20日至2024年5月10日间合计减持599.85万股，占公司目前总股本的0.8186%，变动期间该股股价上涨2.96%，截止5月10日收盘报28.85元。股东增减持详情见下表：根据派林生物2024年一季报公布的十大股东详情如下：以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000044513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2434853689","title":"派林生物(000403.SZ)股东杨峰完成减持599.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434853689","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434853689?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:19","pubTimestamp":1715343598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司股东杨峰累计减持公司股份599.85万股，占总股本比例0.82%，本次减持计划已实施完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2434120830","title":"派林生物获西南证券买入评级，业绩符合预期，浆量迎增长拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2434120830","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434120830?lang=zh_cn&edition=full","pubTime":"2024-05-10 19:38","pubTimestamp":1715341102,"startTime":"0","endTime":"0","summary":"5月10日，派林生物获西南证券买入评级，近一个月派林生物获得6份研报关注。研报预计公司2024-2026年归母净利润7.8亿元，8.9亿元，10.2亿元，对应估值分别为28倍、25倍、21倍。研报认为，公 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240510/c657718785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["000403","600369"],"gpt_icon":0},{"id":"2434069775","title":"派林生物：5月7日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2434069775","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434069775?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:28","pubTimestamp":1715246933,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年5月9日派林生物发布公告称公司于2024年5月7日召开业绩说明会。2023 年度广东双林及派斯菲科采浆量均超过 400 吨，新疆浆站供浆量约 300 吨。广东双林生产车间建设项目投产后，对生产能力预计的升水平。派林生物2024年一季报显示，公司主营收入4.36亿元，同比上升67.0%；归母净利润1.22亿元，同比上升116.31%；扣非净利润1.08亿元，同比上升196.85%；负债率13.46%，投资收益864.58万元，财务费用-1345.73万元，毛利率51.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2433728603","title":"派林生物(000403.SZ)：鸡西浆站获得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2433728603","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433728603?lang=zh_cn&edition=full","pubTime":"2024-05-08 20:18","pubTimestamp":1715170699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司全资子公司哈尔滨派斯菲科生物制药有限公司下属鸡西市东海派斯菲科单采血浆有限公司(简称“鸡西浆站”)收到黑龙江省卫生健康委员会签发的《单采血浆许可证》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2433424997","title":"派林生物最新公告：子公司下属鸡西浆站获得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424997","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433424997?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:31","pubTimestamp":1715167885,"startTime":"0","endTime":"0","summary":"派林生物公告，公司全资子公司哈尔滨派斯菲科生物制药有限公司下属鸡西市东海派斯菲科单采血浆有限公司（简称“鸡西浆站”）收到黑龙江省卫健委签发的《单采血浆许可证》。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800035180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2431033569","title":"派林生物：4月28日召开业绩说明会，包括知名机构磐耀资产的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2431033569","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431033569?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:55","pubTimestamp":1714449316,"startTime":"0","endTime":"0","summary":"派林生物2024年一季报显示，公司主营收入4.36亿元，同比上升67.0%；归母净利润1.22亿元，同比上升116.31%；扣非净利润1.08亿元，同比上升196.85%；负债率13.46%，投资收益864.58万元，财务费用-1345.73万元，毛利率51.42%。该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为33.12。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2431387442","title":"中邮证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431387442","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431387442?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:14","pubTimestamp":1714446884,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司蔡明子,陈成近期对派林生物进行研究并发布了研究报告《采浆量大幅增长，盈利能力有望稳步提升》，本报告对派林生物给出买入评级，当前股价为29.61元。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为33.12。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000403"],"gpt_icon":0},{"id":"2430852447","title":"图解派林生物年报：第四季度单季净利润同比增20.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430852447","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430852447?lang=zh_cn&edition=full","pubTime":"2024-04-27 00:58","pubTimestamp":1714150698,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物2023年年报显示，公司主营收入23.29亿元，同比下降3.18%；归母净利润6.12亿元，同比上升4.25%；扣非净利润5.65亿元，同比上升9.08%；其中2023年第四季度，公司单季度主营收入9.54亿元，同比上升4.63%；单季度归母净利润2.86亿元，同比上升20.34%；单季度扣非净利润2.95亿元，同比上升34.95%；负债率14.0%，投资收益740.21万元，财务费用-5757.18万元，毛利率51.48%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700001790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"gpt_icon":0},{"id":"2430207835","title":"派林生物(000403.SZ)发一季度业绩，净利润1.22亿元，同比增长116.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430207835","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430207835?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:52","pubTimestamp":1714146763,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)发布2024年第一季度报告，营业收入4.35亿元，同比增长67.00%。归属于上市公司股东的净利润1.22亿元，同比增长116.31%。归属于上市公司股东的扣除非经常性损益的净利润1.08亿元，同比增长196.85%。基本每股收益0.1669元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-06-28","address":"山西省太原市晋源区长兴南街8号阳光城环球金融中心3004室","stockEarnings":[{"period":"1week","weight":0.0425},{"period":"1month","weight":0.0131},{"period":"3month","weight":-0.0361},{"period":"6month","weight":0.034},{"period":"1year","weight":0.4072},{"period":"ytd","weight":0.0283}],"companyName":"派斯双林生物制药股份有限公司","boardCode":"AI0027","perCapita":"38535股","boardName":"医药制造业","registeredCapital":"73304万元","compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.0236},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":0.0074}],"survey":"　　派斯双林生物制药股份有限公司主营业务为血液制品的研究、开发、生产和销售，公司主要产品为人血白蛋白、静注人免疫球蛋白(pH4)、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ。","serverTime":1719955124990,"listedPrice":3.78,"stockholders":"17853人(较上一季度增加3.12%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派林生物,000403,派林生物股票,派林生物股票老虎,派林生物股票老虎国际,派林生物行情,派林生物股票行情,派林生物股价,派林生物股市,派林生物股票价格,派林生物股票交易,派林生物股票购买,派林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}